Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Farhat Nasim

Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Farhat Nasim

Articles By : Farhat Nasim

Like USFDA, we need Bharat Food and Drug Administration for global benchmarks, says FM Sitharaman

Farhat Nasim24 Nov 2024 9:30 AM IST

Bengaluru: India is setting standards in pharmaceuticals and like the US Food and Drug Administration (FDA), we should also aim to create Bharat Food...

No More Physical WHO-GMP Certificate Applications After August 15: DCGI Alerts Pharma Firms

DCGI Warns Cosmetic Industry Against Overlapping Claims With Pharma Products

Farhat Nasim23 Nov 2024 3:07 PM IST

New Delhi: The Drugs Controller General of India (DCGI) has issued a stern warning to the cosmetics industry to adhere to strict regulatory...

Boehringer Ingelheim, LEO Pharma collaborate

Dr Reddy's, Aurobindo Pharma, 4 Others Ink MoUs for Rs 5,260 Crore Pharma City Investment

Farhat Nasim23 Nov 2024 1:45 PM IST

The companies have committed to invest over Rs 5,260 crore, which is expected to create 12,490 job opportunities in the pharma sector

Punjab: Tribunal Slaps Rs 5 Crore Interim Fine on Pharma Unit for Violations

Farhat Nasim23 Nov 2024 1:27 PM IST

The NGT bench also directed the PSPCB to initiate criminal proceedings against the pharma unit for past violations

Setback to Torrent: CDSCO Panel Rejects Phase III Waiver Plea for Prucalopride Over Safety Data Gaps

Torrent Pharma Receives USFDA Clearance for Pithampur Facility with VAI Classification

Farhat Nasim23 Nov 2024 12:49 PM IST

Mumbai: Torrent Pharmaceuticals Limited has announced that the company received an Establishment Inspection Report (EIR) from the United States...

US Tariffs May Pressure Indian Pharma, Threaten Biocon Revenues: Fitch

GSK's Augmentin Leads Indian Pharma Market in October with Rs 843 Crore Sales: Pharmatrac Report

Farhat Nasim22 Nov 2024 5:40 PM IST

New Delhi: As the Indian Pharmaceutical Market (IPM) continues its upward trajectory, Augmentin by GlaxoSmithKline (GSK) has stood the test of time...

Marksans Pharma gets USFDA nod for heartburn drug

Marksans Pharma Secures USFDA Nod for Generic Version of Clartin Tablet

Farhat Nasim22 Nov 2024 3:03 PM IST

Marksans' product, Loratadine Tablets USP 10 mg are indicated for the treatment of allergic rhinitis.

Pfizer Names Chris Boshoff as New Chief Scientific Officer, R&D Chief

Farhat Nasim22 Nov 2024 2:41 PM IST

Chris Boshoff will take on the role of chief scientific officer starting Jan 1 & oversee all functions of research & development across all...

After Manipal Hospitals, PMC warns all private hospitals against withholding dead bodies over unpaid bills

Unexo Lifesciences Faces USFDA Heat Over Serious CGMP Violations

Farhat Nasim22 Nov 2024 2:13 PM IST

In response to the issues, the USFDA recommended a voluntary recall of all drug products manufactured at Unexo's facility for the U.S. market.

Wockhardt Founder Seeks GST Exemption on India-Discovered Antibiotics to Enhance Affordability

Farhat Nasim22 Nov 2024 1:19 PM IST

At an event celebrating India's first indigenously developed antibiotic, Nafithromycin, Khorakiwala highlighted the disparity in GST.

Jazz Pharma's Ziihera Gets USFDA Nod To Treat HER2-Positive Biliary Tract Cancer

Farhat Nasim22 Nov 2024 12:30 PM IST

The drug zanidatamab-hrii, sold under the brand name Ziihera, is approved for use in previously treated adults with metastatic HER2-positive biliary...

Cipla Bommasandra facility gets VAI classification from USFDA

Setback to Cipla: DoP rejects plea challenging NPPA order for Acivir Tablets pricing

Farhat Nasim21 Nov 2024 6:16 PM IST

New Delhi: The Department of Pharmaceuticals (DoP) has rejected Cipla Ltd's review application challenging the ceiling price fixed for Acivir 800 mg...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok